Bunka says this new version provides significant improvements geared for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical and supplement markets, as well as for cannabis.
Investor deep dive
Lexaria Bioscience is seeing increased demand for its DehydraTECH drug delivery system
Lexaria Bioscience formulates enhanced DehydraTECH for more efficient cannabis delivery
Quick facts: Lexaria Bioscience Corp
Market Cap: $74.71 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE